
THE IMPACT OF IgA NEPHROPATHY (IgAN)

On the lives of patients and care partners in the US



For more information, please visit <u>ClinicalTrials.gov NCT05200871</u>.

^a Standard questionnaires used in this survey included those developed by researchers to assess kidney disease burden and symptoms, the impact of health on everyday life, anxiety, depression, and impacts on work and other activities.

^b Reflects proportion of people who reported moderate to severe symptoms of depression or anxiety. For comparison, in the general US population, approximately 1 in 14 adults report moderate to severe depression and approximately 1 in 17 adults report moderate to severe anxiety.²

References: 1. Szklarzewicz J, et al. The humanistic burden of rare kidney diseases: understanding the impact of immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) on patients and care-partners study (HONUS): updated results for IgAN in the United States (US). Poster presented at: 60th European Renal Association Congress; June 15-18, 2023; Milan, Italy and virtual. 2. Zablotsky B, et al. National Health Statistics Report. Assessing anxiety and depression: a comparison of National Health Interview survey measures. July 11, 2022.

TRAVERE